2024-10-11 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis

**1. Performance Comparison:**

Johnson & Johnson (JNJ), a multinational pharmaceutical, medical device, and consumer packaged goods company, has underperformed the S&P 500 (VOO) significantly. Its cumulative return of 34.07% is significantly lower than the S&P 500's 134.82%. The relative divergence of -97.9 indicates that JNJ has lagged behind the S&P 500 by a substantial margin, placing it in the bottom 6.56% of its historical performance range.

**2. Recent Price Movement:**

* **Closing Price:** $160.65
* **5-day Moving Average:** $160.13
* **20-day Moving Average:** $162.78
* **60-day Moving Average:** $161.59

JNJ's current price is slightly below its 5-day moving average, indicating a short-term downward trend. However, it remains above both the 20-day and 60-day moving averages, suggesting longer-term support. 

**3. Technical Indicators:**

* **RSI:** 30.23
* **PPO:** -0.29
* **Delta_Previous_Relative_Divergence:** -11.78
* **Expected Return:** 0.0%

The RSI value of 30.23 suggests that JNJ is currently in oversold territory, potentially indicating a bounce back. However, the negative PPO (-0.29) and the negative Delta_Previous_Relative_Divergence (-11.78) point to a short-term bearish trend. The expected return of 0.0% suggests a potential for limited gains over the next five years, compared to the S&P 500.

**4. Recent Earnings and Outlook:**

| Date       | EPS       | Revenue      |
|------------|------------|--------------|
| 2024-07-25 | 1.95       | $22.45 B      |
| 2024-05-01 | 1.35       | $21.38 B      |
| 2024-02-16 | 1.68       | $21.39 B      |
| 2023-10-27 | 10.32      | $21.35 B      |
| 2024-02-16 | 10.32      | $21.35 B      |

While the most recent earnings report for Q2 2024 showed a decline in EPS to 1.95, it exceeded analyst estimates. Revenue also surpassed expectations. The company's strong performance in consumer health and pharmaceuticals continues to drive growth. However, challenges remain, including the ongoing legal battles related to its talcum powder products. Analysts are cautiously optimistic about JNJ's long-term prospects, but potential legal costs and market competition could impact future performance.

**5. News and Recent Issues:**

* **Recent Market Outlook:** JNJ's stock price has been relatively stable in recent months, though it remains below its 52-week high.  Some analysts believe JNJ is undervalued and poised for a rebound due to its strong business model, consistent dividend payments, and potential for growth in emerging markets.
* **Analyst Opinions:**  Analysts are mixed on JNJ's future prospects. Some analysts believe the stock is undervalued and see potential for growth. Others are concerned about the ongoing legal battles related to talcum powder products and the impact on the company's reputation and earnings. 
* **Performance Highlights:**  JNJ has a history of consistent dividend payments, making it attractive to income-oriented investors. Its strong performance in pharmaceuticals and consumer health continues to drive growth in the long term.

**6. Overall Analysis:**

JNJ has been a strong performer historically, but its recent underperformance compared to the S&P 500 has been a cause for concern. While the stock is currently in oversold territory and has the potential for a bounce back, the negative technical indicators and challenges related to legal battles suggest caution. The consistent dividend payments and potential for growth in emerging markets remain attractive to investors. However, investors should carefully consider the risks and potential impact of ongoing legal issues before making an investment decision. 

**7.  Recommendations:**

Based on the analysis, it's recommended to:

* **Monitor closely:** Continue monitoring JNJ's performance and news updates related to the company's legal battles and overall market trends.
* **Diversify:**  Maintain a diversified investment portfolio with other stocks and asset classes to mitigate risk. 
* **Seek professional advice:** Consult with a financial advisor to assess your individual investment goals and risk tolerance before making any investment decisions. 
